Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
eye disease
Biotech
Beacon attracts $170M series B to fund eye disease gene therapy
The British gene therapy biotech will use the funds to push its lead eye disease candidate through a phase 2/3 trial.
James Waldron
Jul 3, 2024 5:00am
Innovent's anti-VEGF drug matches Eylea in eye disease trial
Mar 19, 2024 10:36am
MeiraGTx gifts last of gene therapy rights to J&J for $415M
Dec 21, 2023 10:14am
ProQR, Théa ink new pact for eye assets after old one collapsed
Dec 8, 2023 11:01am
RetinAI Medical joins non-profit macular degeneration initiative
Nov 29, 2023 11:36am
Kodiak resurrects eye drug after ph. 3 data renew approval plans
Nov 6, 2023 8:40am